Reducing carbon impact of inhalers
Find out about the carbon impact of different inhaler types and more about the Ellipta device on our device & dosing page.
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
has been added to your basket
59
At £44.50 Trelegy Ellipta costs less than commonly prescribed multiple inhaler triple therapies in the UK¹ ²
Cost of Trelegy Ellipta compared to other branded multiple inhaler triple therapy combinations in COPD:
*Spiriva HandiHaler; NB: All doses stated are delivered doses. BUD, budesonide; FOR, formoterol; FP, fluticasone propionate; mcg, microgram; MITT, multiple inhaler triple therapies; SAL, salmeterol; SITT, single inhaler triple therapy TIO, tiotropium; FF, fluticasone furoate; UMEC, umeclidinium; VI, vilanterol
SERETIDE (Salmeterol xinafoate/fluticasone propionate) Prescribing Information
Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β₂-agonist or a combination of a long-acting β₂-agonist and a long-acting muscarinic antagonist.⁶
Trelegy Ellipta is generally well tolerated. Common adverse reactions include: headache, nasopharyngitis, influenza, upper respiratory tract infection, pneumonia, back pain, rhinitis, cough, pharyngitis, arthralgia, sinusitis, oropharyngeal pain, bronchitis, constipation, candidiasis of mouth and throat, urinary tract infection.⁶
In common with other corticosteroid-containing medicines, there is an increased risk of pneumonia in patients with COPD treated with Trelegy Ellipta.⁶
References
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
© 2020 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
Trelegy Ellipta was developed in collaboration with
PM-GB-FVU-WCNT-200006 | July 2020